Scotland’s health technology appraisal (HTA) body, the Scottish Medicines Consortium, has accepted Sanofi’s Dupixent (dupilumab) for treating prurigo nodularis, a rare and chronic skin condition, while England’s NICE has rejected the drug for this indication. Different approaches to comparators used in the studies supporting Sanofi’s submissions are one reason for the diverging decisions.
In February’s raft of recommendations on medicines to be accepted for use on the Scottish National Health Service, the SMC okayed Dupixent for treating adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?